Read by QxMD icon Read

Psychopharmacology Bulletin

Priyanka Ghosh, Omar Viswanath
No abstract text is available yet for this article.
February 15, 2019: Psychopharmacology Bulletin
Raul Felipe Palma-Álvarez, Elena Ros-Cucurull, Josep Antoni Ramos-Quiroga, Carlos Roncero, Lara Grau-López
Cocaine-induced psychotic disorder (CIPD) is one of the most serious consequences of cocaine use. Despite the high frequency of CIPD, specific treatment for CIPD has been scarcely researched. Although supportive measures are the first approach, antipsychotic use is often necessary due to clinical severity and CIPD consequences. We report a 38-years-old man with substance use disorders in methadone maintenance treatment who relapsed on cocaine use and presented CIPD that was satisfactorily treated with asenapine...
February 15, 2019: Psychopharmacology Bulletin
Roland van Rensburg, Eric H Decloedt
Neuroleptic malignant syndrome is a rare, idiosyncratic emergency associated with exposure to dopamine antagonists, commonly antipsychotic drugs. The typical clinical picture consists of altered consciousness, muscular rigidity, fever, and autonomic instability. While the condition has generally been well described, the pathophysiology is still poorly understood. The importance of this case report is to highlight the lack of robust evidence-based treatment for this emergency. We submit an approach to the pharmacotherapy of neuroleptic malignant syndrome based on the available evidence...
February 15, 2019: Psychopharmacology Bulletin
Gangaparameswari Soundarrajan, Bharti Chogtu, Vybhava Krishna, Avinash Kamath G, Manisha Murugesan
Akathisia is a common movement disorder that occurs as a consequence of antipsychotic therapy. However, its occurrence secondary to risperidone withdrawal has been reported rarely. Reporting of such rare adverse event gains profound importance because changing the antipsychotics is very common in long term management of affective disorders. Here, we report a 17-year-old female who on withdrawal of risperidone developed akathisia. Further, we also discuss already reported cases in literature in relation to the current case...
February 15, 2019: Psychopharmacology Bulletin
Antonio Siniscalchi, Giovambattista De Sarro, Roberta Pacifici, Ermanno Pisani, Sandro Sanguigni, Luca Gallelli
Alteplase is the main pharmacological treatment available for intravenous thrombolysis in patients with acute ischemic stroke. Endovascular treatment alone or add-on to intravenous thrombolysis is a valid approach in acute ischemic stroke with cerebral large vessel disease. The most common serious adverse reaction related to alteplase is the development of spontaneous intracerebral hemorrhage and the presence of cerebral small vessel disease may increase this risk, particularly in cocaine users, even if only few data have been published on this topic...
February 15, 2019: Psychopharmacology Bulletin
Steven J Girdler, Jamie E Confino, Mary E Woesner
Schizophrenia is a mental disorder that is characterized by progressive cognitive impairment in areas of attention, working memory, and executive functioning. Although no clear etiology of schizophrenia has been discovered, many factors have been identified that contribute to the development of the disease, such as neurotransmitter alterations, decreased synaptic plasticity, and diminished hippocampal volume. Historically, antipsychotic medications have targeted biochemical alterations in the brains of patients with schizophrenia but have been ineffective in alleviating cognitive and hippocampal deficits...
February 15, 2019: Psychopharmacology Bulletin
Sarah J Choi, Roberta Storey, Sagar V Parikh, Jolene R Bostwick
Objectives: To enhance depression care by improving medication information available prior to initial patient consultations. Experimental Design and Sample: Single-center, with intervention delivered to all new patient referrals at a tertiary care depression clinic. Trained pharmacy students utilizing a standard script prior to the first consultation visit conducted a medication review and depression treatment telephone assessment. Results: From 225 individuals contacted once by phone in the week prior to scheduled initial consultation, 141 (62...
February 15, 2019: Psychopharmacology Bulletin
Camilla Callegari, Marta Ielmini, Ivano Caselli, Giulia Lucca, Celeste Isella, Marcello Diurni, Fabiana Pettenon, Nicola Poloni
Background: The impact of menopause is a consequence of social, physical and mental changes; hormonal changes play an important role in inducing an increased risk of developing depressive symptoms. It is essential to treat mood and vasomotor symptoms and to prevent their onset to promote an improvement in the quality of life, both in terms of clinical and psychological conditions. Objective: This observational study aims to compare paroxetine and vortioxetine in a sample of patients affected by postmenopausal depression attending the Anxiety and Depression Clinic in terms of: efficacy in determining clinical remission (HDRS ≤ 7) and tolerability; improvement of autonomic and cognitive symptoms...
February 15, 2019: Psychopharmacology Bulletin
Nina Vadiei, Tawny L Smith, Amy E Walton, Kimberly L Kjome
Introduction: Benzodiazepines are currently the gold standard for treatment of alcohol withdrawal. Gabapentin has growing evidence to support its use in the treatment of alcohol use disorder, however there is limited evidence regarding its role in the treatment of alcohol withdrawal. The purpose of this study was to determine if adjunctive gabapentin reduces the need for benzodiazepine (BZD) administration during alcohol withdrawal. Methods: This was a retrospective single-center cohort study...
February 15, 2019: Psychopharmacology Bulletin
Murat Altinay, Harish Karne, Amit Anand
Introduction and Background: Patients with depression who fail to respond to at least two antidepressants in their current episode are considered to have Treatment Resistant Depression (TRD). ECT is an effective treatment of TRD but cognitive side effects limit its use. Ketamine elicits a rapid antidepressant response in sub-anesthetic repeated doses. ECT and ketamine may be modulating the glutamate system, therefore when administered in an interleaved fashion, they could have a synergistic effect...
February 15, 2019: Psychopharmacology Bulletin
(no author information available yet)
[This retracts the article on p. 8 in vol. 47.][This retracts the article on p. 17 in vol. 47, PMID: 28839336.].
June 20, 2018: Psychopharmacology Bulletin
Willie R Earley, Hua Guo, György Németh, Judit Harsányi, Michael E Thase
Cariprazine is an atypical antipsychotic currently under investigation as an adjunctive to antidepressant treatment (ADT) for patients with major depressive disorder (MDD). Here results of an 18- to 19-week randomized double-blind placebo-controlled Phase 3 study evaluating the efficacy of adjunctive cariprazine (1.5-4.5 mg/day[d]) with ADT in participants with previous inadequate response to ADT are presented. ADT response was assessed in an 8-week open-label period; inadequate responders were randomized (N = 530) to open-label ADT plus placebo (n = 261) or cariprazine (n = 269) for the 8-week double-blind phase (NCT01715805)...
June 20, 2018: Psychopharmacology Bulletin
Sofia Medrano, Amal Abdel-Baki, Emmanuel Stip, Stéphane Potvin
Abstract: Poor adherence to antipsychotics, which affects outcome, is frequent in first episode psychosis (FEP). Most randomized studies demonstrate no superiority of long-acting injectable antipsychotics (LAI-AP) over oral antipsychotics (OAP). However, participants in these studies represent a minority of patients who may benefit from LAI-AP. Mirror and naturalistic studies generally demonstrate efficacy of LAI-AP on more representative samples, but studies on FEP are scarce. Aim: To describe LAI-AP's utilization and impact on FEP outcome in a naturalistic setting...
June 20, 2018: Psychopharmacology Bulletin
Sereen Rose Thomson, Navin Patil, Balaji Ommurugan, Rajesh Krishna Bhandary
Introduction: Schizophrenia treatment needs to cover several psychological interventions and pharmacological treatment for stabilizing the disease course and decreasing relapses. Sexual side effects are a major hindrance to patients and lead to decreased adherence to therapy and reduced quality of life. Recently, several studies outlined that sexual dysfunction is one of the most distressing side effects of antipsychotics and a major cause of a poor quality of life. We hereby report a case of hypersexuality probably associated with clozapine in a middle-aged woman with schizoaffective disorder...
June 20, 2018: Psychopharmacology Bulletin
Johan Y Cohen, Amélie Guilbault
Due to the stringent regulatory environment for therapeutics, common side-effects of drugs in the general population are largely well-documented. This is however less the case with certain patient subgroups who may exhibit significant adverse responses to therapeutics that are otherwise well-tolerated. We report a case of psychosis induced by exposure to a commonly prescribed drug to treat muscle spasms and associated pain cyclobenzaprine (Flexeril®). Cyclobenzaprine is structurally very similar to tricyclic anti-depressants, such as amyltriptine...
June 20, 2018: Psychopharmacology Bulletin
Omar Viswanath
No abstract text is available yet for this article.
June 20, 2018: Psychopharmacology Bulletin
Jacquelin Peck, Omar Viswanath
No abstract text is available yet for this article.
June 20, 2018: Psychopharmacology Bulletin
Marcela Almeida, Heather Burrell Ward
No abstract text is available yet for this article.
June 20, 2018: Psychopharmacology Bulletin
Dipanjan Bhattacharjee, Devesh Yerrapragada, Bharti Chogtu, Sereen R Thomson
No abstract text is available yet for this article.
March 13, 2018: Psychopharmacology Bulletin
Raghavendra S Rao, Shubha Sheshadri, Dipanjan Bhattacharjee, Navin Patil, Karthik Rao
Progressive non-familial adult onset cerebellar degeneration has been rarely associated with hypothyroidism and is known to be reversible after therapy. We report a case of cerebellar atrophy in a 31 year old female whose detailed evaluation had revealed sub-clinical hypothyroidism secondary to autoimmune thyroiditis with a very high anti-TPO (anti-thyroid peroxidase) antibody levels. MRI (Magnetic Resonanace Imaging) of brain showed diffuse bilateral cerebellar atrophy. She was treated with thyroid hormone supplementation and after one year of follow up, cerebellar signs had disappeared completely with significant reduction in anti-TPO antibody levels...
March 13, 2018: Psychopharmacology Bulletin
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"